Home Cart Sign in  
Chemical Structure| 67139-22-4 Chemical Structure| 67139-22-4

Structure of 67139-22-4

Chemical Structure| 67139-22-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 67139-22-4 ]

CAS No. :67139-22-4
Formula : C6H9N3
M.W : 123.16
SMILES Code : C12=NC=CN1CCCN2
MDL No. :MFCD08273903
InChI Key :VCZBRPRKZKPDQD-UHFFFAOYSA-N
Pubchem ID :135625409

Safety of [ 67139-22-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Computational Chemistry of [ 67139-22-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 5
Fraction Csp3 0.5
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 38.42
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

29.85 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.15
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.4
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.13
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.11
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.58
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.47

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.27
Solubility 6.66 mg/ml ; 0.0541 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.59
Solubility 31.4 mg/ml ; 0.255 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.25
Solubility 6.99 mg/ml ; 0.0568 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.77 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.95

Application In Synthesis of [ 67139-22-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 67139-22-4 ]

[ 67139-22-4 ] Synthesis Path-Downstream   1~7

  • 1
  • [ 274-95-3 ]
  • [ 67139-22-4 ]
  • 3
  • di-tert-butyl (2-((2-(N,N-bis(4-methoxybenzyl)sulfamoyl)-4-iodo-3-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)phenyl)sulfonamido)propane-1,3-diyl)dicarbamate [ No CAS ]
  • [ 67139-22-4 ]
  • di-tert-butyl (2-((2-(N,N-bis(4-methoxybenzyl)sulfamoyl)-4-(6,7-dihydroimidazo[1,2-a]pyrimidin-8(5H)-yl)-3-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)phenyl)sulfonamido)propane-1,3-diyl)dicarbamate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With methanesulfonato[2,2'-bis(diphenylphosphino)-1,1'-binapthyl](2'-amino-1,1'-biphenyl-2-yl)palladium (II); caesium carbonate; In 1,2-dimethoxyethane; at 80℃;Inert atmosphere; To di-tert-butyl (2-(2-(N,N-bis(4-methoxybenzyl)sulfamoyl)-4-iodo-3-(2-(4- methoxybenzyl)-2H-tetrazol-5-yl)phenylsulfonamido)propane-1,3-diyl)dicarbamate (from EXAMPLE 10 Step A) (250 mg, 0.235 mmol) and <strong>[67139-22-4]5,6,7,8-tetrahydroimidazo[1,2-a]pyrimidine</strong> (57.9 mg, 0.470 mmol), Cs2CO3 (230 mg, 0.706 mmol), and RAC-BINAP-PD-G3 precatalyst (46.7 mg, 0.047 mmol) were added DME (3 mL) at RT and the mixture was degassed for 10 min. The reaction mixture was then stirred at 80 C overnight. The mixture was diluted with water (50 mL), extracted with CH2Cl2 (2 x 50 mL). The combined organic phases were washed with brine, dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with 0 - 30% heptane/ethanol in 30 min to give title product. LC/MS [M+H]+: 1058.
  • 4
  • [ 67139-22-4 ]
  • N1-(1,3-diaminopropan-2-yl)-4-(6,7-dihydroimidazo[1,2-a]pyrimidin-8(5H)-yl)-N2-(4-methoxybenzyl)-3-(2-(4-methoxybenzyl)-2H-tetrazol-5-yl)benzene-1,2-disulfonamide [ No CAS ]
  • 5
  • [ 67139-22-4 ]
  • N1-(1,3-diaminopropan-2-yl)-4-(6,7-dihydroimidazo[1,2-a]pyrimidin-8(5H)-yl)-3-(2H-tetrazol-5-yl)benzene-1,2-disulfonamide [ No CAS ]
  • 6
  • [ 24424-99-5 ]
  • [ 67139-22-4 ]
  • tert-butyl 3-bromo-6,7-dihydroimidazo[1,2-a]pyrimidine-8(5H)-carboxylate [ No CAS ]
  • 7
  • [ 24424-99-5 ]
  • [ 67139-22-4 ]
  • C11H17N3O2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
67% With dmap; triethylamine; In dichloromethane; at -10 - 20℃;Inert atmosphere; To a cooled to -10 C. solution of compound 18 (24.8 g, 201 mmol), triethylamine (24.5 g, 242 mmol), and DMAP (2.46 g, 20.1 mmol) in dichloromethane (450 mL), Boc2O (52.8 g, 242 mmol) was added dropwise. The mixture was stirred for 30 min at -10 C., then warmed to r.t. and left to stir overnight. The next day the reaction mixture was evaporated under vacuum. The residue was subjected to silica gel column chromatography to give 30.0 g (134 mmol, 67%) of compound 19.
 

Historical Records

Categories

Related Parent Nucleus of
[ 67139-22-4 ]

Other Aromatic Heterocycles

Chemical Structure| 1209264-64-1

A421790 [1209264-64-1]

5,6,7,8-Tetrahydroimidazo[1,2-a]pyrimidine hydrochloride

Similarity: 0.98

Chemical Structure| 67139-25-7

A543838 [67139-25-7]

6,7,8,9-Tetrahydro-5H-imidazo[1,2-a][1,3]diazepine

Similarity: 0.92

Chemical Structure| 67139-08-6

A601071 [67139-08-6]

2,3-Dihydro-1H-imidazo[1,2-a]imidazole

Similarity: 0.83